Sweden's Ascelia Pharma Q1 loss narrows

Ascelia Pharma AB

12/05/2026 06:39

Overview

Sweden orphan oncology biotech's Q1 operating loss narrowed yr/yr

Q1 EPS improved to SEK -0.13 from SEK -0.23 yr/yr

Company completed SEK 20 mln share issue after quarter to extend cash runway

Outlook

Recent capital raise extends cash runway into 2027, enhancing flexibility for partnering negotiations

Result Drivers

ORVIGLANCE DEVELOPMENT - Co said FDA review of Orviglance progressed as planned, with approval decision expected in July

CAPITAL RAISE - SEK 20 mln share issue completed after quarter to extend cash runway and support partnering talks

Company press release: ID:nMFN2pjzbh

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-SEK 0.13
Q1 Cash Flow From Operations
-SEK 15.90 mln


Analyst Coverage

Wall Street's median 12-month price target for Ascelia Pharma AB is SEK7.50, about 157.3% above its May 11 closing price of SEK2.92

The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 31 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)